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abstractBACKGROUND: The Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) 
trial found that recurrent urinary tract infections (rUTI) with resistant organisms were 
more common in the trimethoprim-sulfamethoxazole prophylaxis (TSP) arm. We describe 
factors associated with trimethoprim-sulfamethoxazole (TMP-SMX) resistance of rUTIs in 
RIVUR.
METHODS: Children aged 2 to 71 months with first or second UTI (index UTI) and grade I to IV 
vesicoureteral reflux (VUR) were randomized to TSP or placebo and followed for 2 years. 
Factors associated with TMP-SMX–resistant rUTI were evaluated.
RESULTS: Among 571 included children, 48% were <12 months old, 43% had grade II VUR, and 
38% had grade III VUR. Recurrent UTI occurred in 34 of 278 children receiving TSP versus 
67 of 293 children receiving placebo. Among those with rUTI, 76% (26/34) of subjects 
receiving TSP had TMP-SMX–resistant organisms versus 28% (19/67) of subjects receiving 
placebo (P < .001). The proportion of TMP-SMX–resistant rUTI decreased over time: in the 
TSP arm, 96% were resistant during the initial 6 months versus 38% resistant during the 
final 6 months; corresponding proportions for the placebo arm were 32% and 11%. Among 
children receiving TSP, 7 (13%) of 55 with TMP-SMX–resistant index UTI had rUTI, whereas 
27 (12%) of 223 with TMP-SMX–susceptible index UTI had rUTI (adjusted hazard ratio 
1.38, 95% confidence interval 0.54–3.56). Corresponding proportions in placebo arm were 
17 (26%) of 65 and 50 (22%) of 228 (adjusted hazard ratio 1.33, 95% confidence interval 
0.74–2.38).
CONCLUSIONS: Although TMP-SMX resistance is more common among children treated with 
TSP versus placebo, resistance decreased over time. Among children treated with TSP, there 
was no significant difference in UTI recurrence between those with TMP-SMX–resistant 
index UTI versus TMP-SMX–susceptible UTI.
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WHAT’S KNOWN ON THIS SUBJECT: Although 
antimicrobial prophylaxis is effective in preventing 
recurrent urinary tract infection (UTI) in children with 
vesicoureteral refl ux, increased antibiotic resistance 
is a concern. However, little is known about patterns of 
resistance over time with prophylaxis, and whether index 
UTI resistance affects prophylaxis effi cacy.
WHAT THIS STUDY ADDS: Although trimethoprim-
sulfamethoxazole (TMP-SMX) resistance is more 
common among children with refl ux treated with TMP-
SMX prophylaxis, resistance decreased over time, in 
both treatment and placebo groups. Index UTI TMP-SMX 
resistance was not associated with recurrent UTI, among 
those treated with TMP-SMX prophylaxis.
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Children diagnosed with 
vesicoureteral reflux (VUR) after 
a urinary tract infection (UTI) are 
commonly treated with antimicrobial 
prophylaxis, to reduce the risk of 
recurrent UTI (rUTI). Although there 
has been controversy in recent years 
regarding utilization of antimicrobial 
prophylaxis to prevent rUTI, the 
recent Randomized Intervention 
for Children with Vesicoureteral 
Reflux (RIVUR) trial demonstrated 
convincingly that the incidence of 
recurrent febrile or symptomatic 
UTI (F/SUTI) is lower among children 
with VUR treated with trimethoprim-
sulfamethoxazole prophylaxis (TSP) 
compared with those receiving 
placebo.1
RIVUR trial outcomes were also 
significant for the finding that among 
participants who developed a first 
recurrence of F/SUTI with Escherichia 
coli, the proportion of isolates that 
were resistant to trimethoprim-
sulfamethoxazole (TMP-SMX) 
was 63% with TSP and 19% with 
placebo (P < .001). However, space 
limitations in the primary RIVUR 
results report precluded extensive 
discussion of characteristics and 
resistance patterns of recurrent F/
SUTIs in the trial.
Data regarding TMP-SMX resistance 
of the index (preenrollment) F/
SUTI were also collected. In clinical 
practice, some assume that the 
antibiotic-resistance pattern of 
the initial UTI should be used 
to determine the appropriate 
agent for prophylaxis, rather than 
the side-effect profile or ease of 
administration of the agent. Limited 
evidence is available to support this 
assumption, 2 and the problem is 
difficult to study in an uncontrolled 
retrospective setting, as the clinical 
choice of prophylaxis agent is so 
often based on the resistance pattern 
of the index UTI, rendering the 
sample biased. The RIVUR study 
allowed for a natural experiment, 
because all children randomized to 
the active agent received TMP-SMX 
regardless of the resistance pattern 
of the index UTI, giving us the 
opportunity to analyze rUTI rates in 
this unbiased sample.
The aims of this analysis were 
twofold: (1) to characterize patterns 
of antimicrobial resistance among 
recurrent F/SUTIs in the RIVUR 
trial, and (2) to determine whether 
resistance of the index UTI to TMP-
SMX reduces the effectiveness of TSP 
in preventing recurrent F/SUTI.
METHODS
Data Source and Patient Population
The rationale and design of the 
RIVUR trial have been published 
previously.3, 4 Briefly, children aged 
2 to 71 months with a history of 
confirmed first or second febrile or 
symptomatic UTI, and grade I to IV 
VUR, were enrolled at 19 centers in 
the United States. Enrolled children 
were randomized to either TMP-SMX 
or placebo and followed for 2 years, 
with primary outcome of recurrence 
of F/SUTI, and secondary outcomes 
of renal scarring, failure of TSP, and 
antimicrobial resistance. Children 
with non-VUR urologic anomalies, 
or index F/SUTI occurring >112 days 
before randomization, were excluded. 
Of the 607 children randomized in 
the RIVUR trial, this analysis includes 
571 children who had complete data 
for index UTI resistance; 278 children 
in the TSP arm and 293 in the 
placebo arm. Subjects were analyzed 
as randomized (not strictly intention-
to-treat), as we excluded those 
without index UTI sensitivity data.
UTI Defi nitions
Both index and recurrent F/SUTIs 
were defined as clinical events 
meeting all of the following criteria: 
pyuria on urinalysis, culture-proven 
infection with a single organism 
(≥50 000 colony-forming units 
per milliliter for catheterized or 
suprapubic aspirate specimens, 
≥100 000 colony-forming units 
per milliliter for clean voided 
specimens), and fever (≥38°C) or 
urinary tract symptoms (suprapubic, 
abdominal, or flank pain or 
tenderness; or urinary urgency, 
frequency, or hesitancy; or dysuria; 
or foul-smelling urine; or in infants 
≤4 months old: failure to thrive, 
dehydration, or hypothermia) 
within 24 hours before or after urine 
collection.
Resistance of both index and 
recurrent F/SUTIs was based on the 
antibiotic susceptibility profile (the 
“antibiogram”) from the urine culture 
obtained in the course of clinical care. 
These tests were performed by local 
clinical laboratories; urine cultures 
were not processed in a central 
facility. Among children enrolled in 
the RIVUR trial after their second F/
SUTI, resistance classification was 
based on the second F/SUTI, which 
represented the index F/SUTI for the 
trial. F/SUTIs caused by Enterococcus 
were assumed to be resistant to 
TMP-SMX, based on biological 
mechanisms inherent to this 
organism. TMP susceptibility alone 
was reported for 8.8% of recurrent 
F/SUTIs; for analytic purposes these 
were grouped together with those 
reporting TMP-SMX susceptibility.
Timing of resistance for recurrent 
F/SUTI was assessed by comparing 
6-month enrollment periods, 
focusing in particular on resistance 
during the first 6 months versus 
resistance during the last 6 months 
(study period 18–24 months).
Statistical Analysis
We compared participants’ 
characteristics by using Fisher’s exact 
test to compare categorical variables, 
by using a 3-way comparison of 
those without recurrent F/SUTI 
versus those with at least 1 resistant 
recurrent F/SUTI versus those with 
only susceptible recurrent F/SUTI, as 
well as a 2-way comparison between 
those with at least 1 resistant 
recurrent F/SUTI versus those with 
only susceptible recurrent F/SUTI 
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(among those with a recurrent F/
SUTI).
To compare incidence of recurrent 
F/SUTI between children with TMP-
SMX–resistant versus TMP-SMX–
sensitive index F/SUTI, we calculated 
unadjusted and adjusted hazard 
ratios (HRs) for the TMP-SMX group 
only, by using Cox proportional 
hazards regression.. Adjusted 
HRs account for febrile (versus 
nonfebrile) index UTI, resistant 
(versus susceptible) index UTI, age, 
race, ethnicity, VUR grade, bladder 
and bowel dysfunction (BBD), and 
administrative site. BBD was a time-
dependent measure (yes, no, not 
toilet trained, unknown), allowed 
to change up to 4 times over the 
course of the follow-up period, 
and presented as person-years 
of follow-up time. Because most 
subjects did not have the primary 
outcome (recurrent F/SUTI), we 
could not calculate median event-
free survival, and so we calculated 
and reported time to 10% incidence 
(the enrollment time at which 10% 
of at-risk subjects had experienced 
the outcome). The Mantel-Haenszel 
correlation statistic was used to 
compare treatment-group–adjusted 
rates of resistance over 4 time 
periods during the study.
All tests were 2-sided. P values were 
not adjusted for multiple testing. 
Calculations were performed by 
using SAS version 9.3 (SAS Institute, 
Inc, Cary, NC).
RESULTS
Characteristics of the Sample
Demographic and clinical 
characteristics of RIVUR participants 
have been previously reported.1 
For the current study, we excluded 
36 children who lacked adequate 
index UTI resistance data; compared 
with the included sample (n = 571), 
the excluded children (n = 36) had 
a higher proportion randomized 
to active treatment (67% vs 49%), 
fewer index UTIs caused by E coli 
(81% vs 89%), a higher proportion 
with recurrent F/SUTI infections 
(28% vs 18%), and were more likely 
to be white (94% vs 80%). Among 
included children (Table 1), almost 
half (48%) were <1 year of age at 
enrollment and 92% were girls. 
Because the cohort was relatively 
young at enrollment, most (78%) 
were not toilet trained and therefore 
could not be classified with respect 
to BBD at enrollment; of the 122 who 
were toilet trained, 68 (56%) met the 
definition of BBD. Most children had 
grade II (43%) or grade III (38%) 
VUR. The index UTI was resistant 
to TMP-SMX in 21% of cases (20% 
among the TMP-SMX group, 22% 
among the placebo group).
Characteristics of rUTI
Factors associated with incidence 
of recurrent F/SUTI are shown in 
Table 1. A total of 470 children 
had no recurrent F/SUTI during the 
study period, whereas 101 (18%) 
had at least 1 recurrent F/SUTI. A 
number of children had multiple 
recurrences, including 27 children 
with 2 recurrences, 5 children 
with 3 recurrences, and 5 children 
with 4 recurrences. Additional 
characteristics of recurrent F/SUTI 
are shown in Table 2. Although 
67% of recurrences were febrile, 
the remainder presented with 
symptoms other than fever. E coli 
was the causative uropathogen 
isolated in most (82%) recurrences, 
with a range of bacteria making up 
the remainder, including Klebsiella, 
Enterococcus, and Proteus species. 
Enterococcus, assumed to be TMP-
SMX resistant and not tested based 
on the metabolism of the organism, 
comprised 12% (n = 7) of the 
resistant recurrent F/SUTIs. Most 
recurrent F/SUTI episodes were 
treated as outpatients, but 35% of 
events involved either hospitalization 
or an emergency department visit. 
Almost half of the recurrences 
occurred during the first 6 months 
after enrollment; the remaining 
recurrences were split relatively 
evenly between the other three 
6-month blocks.
Antibiotic Susceptibility Among 
Recurrent F/SUTIs
Among the 101 children who 
experienced recurrent F/SUTI, 
45 (45%) had at least 1 
recurrent F/SUTI caused by a 
TMP-SMX–resistant uropathogen, 
whereas 56 (55%) had 
recurrences caused only by TMP-
SMX–susceptible uropathogens. 
The associations of subject 
characteristics with TMP-SMX 
resistance among recurrent F/SUTI 
are shown in Table 1 and Table 2. 
The overall proportion of RIVUR 
participants who had recurrent F/SUTI 
caused by a TMP-SMX–resistant 
uropathogen was slightly larger in 
the TSP arm (26 [9%] of 278 vs 19 
[6%] of 293, odds ratio 1.46, 95% 
confidence interval [CI] 0.80–2.6). 
Conversely, the proportion with only 
susceptible recurrent F/SUTI was 
higher in the placebo group (16% vs 
3%, P < .0001). Among children who 
experienced recurrent F/SUTI, those 
in the TSP arm were more likely to 
have a recurrence caused by a 
TMP-SMX–resistant uropathogen 
(26/34, 76%) compared with 
children in the placebo arm 
(19 [28%] of 67; P < .001). However, 
the proportion of recurrent F/SUTI 
in both the TSP and placebo arms 
caused by TMP-SMX–resistant 
uropathogens decreased over the 
course of the study (Fig 1). For 
children in the TSP arm, 96% of 
recurrent F/SUTIs during the initial 
6 months were caused by a TMP-
SMX–resistant uropathogen; during 
the final 6 months, only 38% of 
recurrent F/SUTIs were caused by 
TMP-SMX–resistant organisms. 
Corresponding proportions during 
the same time periods for children 
in the placebo arm were 32% 
during the initial 6 months and 
11% during the final 6 months. 
The Mantel-Haenszel correlation 
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statistic (P < .0001) also pointed to 
a substantial decrease in resistant 
infections over time.
Figure 2 also shows the 
susceptibility patterns for other 
antimicrobial classes among 
recurrent F/SUTI; TMP-SMX 
resistance was significantly 
associated with resistance to 
4
TABLE 1  Characteristics of RIVUR Subjects by rUTIs
Overall, n = 571, 
n (%)
No rUTI, n = 470, n (%) At Least 1 Resistant 
rUTI, n = 45, n (%)
Subjects With Only 
Susceptible rUTIs, n = 
56, n (%)
Overall Pa R vs S Pb
Total no. of patients <.001 <.001
 TMP-SMX 278 (49) 244 (52) 26 (58) 8 (14)
 Placebo 293 (51) 226 (48) 19 (42) 48 (86)
Age at enrollment, mo .01 .90
 <12 275 (48) 233 (50) 19 (42) 23 (41)
 12–35 179 (31) 154 (33) 12 (27) 13 (23)
 36–72 117 (20) 83 (18) 14 (31) 20 (36)
Gender .35 .32
 Circumcised boys 17 (3) 17 (4) 0 (0) 0 (0)
 Girls 526 (92) 429 (91) 42 (93) 55 (98)
 Uncircumcised boys 28 (5) 24 (5) 3 (7) 1 (2)
Race .05 .03
 Nonwhite 113 (20) 96 (21) 12 (27) 5 (9)
 White 448 (80) 364 (79) 33 (73) 51 (91)
 Hispanic ethnicity .63 .75
 Hispanic 75 (13) 65 (14) 5 (11) 5 (9)
 Other 493 (87) 402 (86) 40 (89) 51 (91)
Highest VUR grade .32 >.99
 I 62 (11) 52 (11) 4 (9) 6 (11)
 II 244 (43) 211 (45) 15 (33) 18 (33)
 III 218 (38) 172 (37) 21 (47) 25 (45)
 IV 44 (8) 33 (7) 5 (11) 6 (11)
VUR laterality .93 >.99
 Bilateral 271 (48) 225 (48) 20 (45) 26 (47)
 Unilateral 292 (52) 239 (52) 24 (55) 29 (53)
Index UTI organism .66 .92
 E coli 509 (89) 417 (89) 41 (91) 51 (91)
 Enterococcus species 13 (2) 12 (3) 1 (2) 0 (0)
 Klebsiella species 18 (3) 15 (3) 1 (2) 2 (4)
 Proteus species 14 (2) 14 (3) 0 (0) 0 (0)
 Other 17 (3) 12 (3) 2 (4) 3 (5)
Index UTI symptoms .50 .41
 Febrile 490 (86) 405 (86) 36 (80) 49 (88)
 Nonfebrile 81 (14) 65 (14) 9 (20) 7 (13)
Index UTI .21 .16
 Resistant 120 (21) 96 (20) 14 (31) 10 (18)
 Susceptible 451 (79) 374 (80) 31 (69) 46 (82)
BBD .003 .83
 No BBD 54 (10) 42 (9) 6 (14) 6 (11)
 BBD 68 (12) 45 (10) 9 (20) 14 (25)
Not toilet trained 441 (78) 376 (81) 29 (66) 36 (64)
History of constipation .72 .82
 No 401 (71) 326 (70) 34 (76) 41 (73)
 Yes 166 (29) 140 (30) 11 (24) 15 (27)
Treated for constipation .72 .75
 No 491 (87) 401 (86) 41 (91) 49 (88)
 Yes 76 (13) 65 (14) 4 (9) 7 (13)
No. of rUTIsc
 0 470 (82) 470 (100) 0 (0) 0 (0)
 1 64 (11) 0 (0) 26 (58) 38 (68)
 2 27 (5) 0 (0) 12 (27) 15 (27)
 3 5 (1) 0 (0) 4 (9) 1 (2)
 4 5 (1) 0 (0) 3 (7) 2 (4)
a P values for an overall comparison of no rUTI, at least 1 resistant UTI, and only susceptible UTIs were computed using Fisher's exact test.
b P value for a comparison of at least 1 resistant UTI versus only susceptible UTIs using Fisher's exact test.
c P values were not computed for number of rUTIs.
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ampicillin/amoxicillin (P < .001), 
gentamicin (P = .02), quinolones 
(P = .003), and cefepime (P = .05).
Association of TMP-SMX Resistance 
in the Index F/SUTI With Recurrence 
of F/SUTI Among Children in the TSP 
Treatment Arm
TMP-SMX resistance status of the 
index F/SUTI was not associated with 
recurrence of F/SUTI among those 
treated with TSP (Table 3). Among 
children in the TSP group who had 
an index F/SUTI resistant to TMP-
SMX, 7 (13%) of 55 had a recurrent 
F/SUTI; among children in the TSP 
group who had an index F/SUTI 
susceptible to TMP-SMX, 27 (12%) 
of 223 had a recurrent F/SUTI. The 
survival analysis for recurrence of F/
SUTI, comparing index-resistant to 
index-susceptible children in the TSP 
treatment arm only, adjusting for 
febrile index UTI, age, race/ethnicity, 
VUR grade, BBD, and geographic 
site, showed an HR of 1.38 (95% CI 
0.54–3.56). Most recurrent F/SUTIs in 
the index-resistant group occurred 
early in the study period, whereas 
recurrences in the index-susceptible 
group were spread throughout the 
length of the study period (Fig 3); 
however, the overall proportion 
with recurrent F/SUTI was similar 
between index-resistant and index-
susceptible groups. Limiting this 
analysis to only the first 6 months of 
the study period still did not show a 
significant difference (HR 2.45, 95% 
CI 0.77–7.85).
DISCUSSION
This analysis of the RIVUR cohort 
data found that, although rUTIs 
occurring in the TSP treatment group 
were more likely to be due to TMP-
SMX–resistant organisms, the overall 
incidence of TMP-SMX–resistant 
rUTI was only slightly higher in 
the treatment group compared 
with placebo (9% vs 6%). The 
proportion of TMP-SMX–resistant 
recurrent F/SUTIs decreased over 
the course of the study, in both the 
placebo and TSP treatment groups. 
We also found that, among those 
in the TSP treatment arm, there 
was no difference in the incidence 
of recurrent F/SUTI between those 
with TMP-SMX–resistant versus –
susceptible index F/SUTI.
This study takes advantage of the 
robust prospective data collection of 
the RIVUR trial. Entry criteria were 
strict and carefully documented, 
the cohort was well-characterized, 
children were followed closely 
during the study (clinic visits every 
6 months and phone contacts 
every 2 months), and retention 
was excellent. However, certain 
limitations should be recognized. 
As noted in the methods section, 
the resistance classifications were 
based on antibiograms provided by 
the clinical laboratories in which 
care was received. There was no 
RIVUR-specific standardization of 
culture or resistance evaluation 
techniques. We can assume that 
clinical laboratories followed 
techniques and operating procedures 
in accordance with state regulations 
and those promoted by professional 
organizations such as the Clinical and 
Laboratory Standards Institute, but 
we have no way of independently 
verifying the techniques used. The 
RIVUR trial itself had limitations, 
including limited generalizability to 
children with different demographic 
or clinical characteristics, and our 
findings apply only to children 
with documented grade I to IV 
VUR. Although compliance with 
study medication was carefully 
documented by using surveys 
administered every 2 months, 
absolute certainty with respect 
to intake of study drug cannot be 
achieved because biosampling 
was not performed for compliance 
assessment purposes.
Previous randomized trials of 
prophylaxis to prevent rUTI in 
children have generally shown that, 
as in the RIVUR trial, resistance 
rates were higher in the treatment 
group. However, almost none of these 
studies have been as thorough in 
documentation of outcomes as the 
RIVUR trial, or of this duration; most 
reported very limited resistance data. 
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TABLE 2  Characteristics of rUTIs
All rUTI, n = 
147, n (%) 
Resistant rUTI, n 
= 58, n (%)
Susceptible rUTI, 
n = 89, n (%)
Pa
Time from RIVUR enrollment, d .004
 0–182 70 (48) 37 (64) 33 (37)
 183–365 27 (18) 11 (19) 16 (18)
 366–547 24 (16) 5 (9) 19 (21)
 >547 26 (18) 5 (9) 21 (24)
Clinical presentation rUTI .15
 Febrile 38 (26) 18 (31) 20 (22)
 Symptomatic 49 (33) 14 (24) 35 (39)
 Febrile AND symptomatic 60 (41) 26 (45) 34 (38)
Recurrent UTI organismb
 E coli 121 (82) 42 (72) 79 (89) .01
 Klebsiella 10 (7) 5 (9) 5 (6) .52
 Enterococcus 7 (5) 7 (12) 0 (0) .001
 Proteus 3 (2) 0 (0) 3 (3) .28
 Enterobacter 2 (1) 1 (2) 1 (1) >.99
 Citrobacter 1 (1) 1 (2) 0 (0) .39
CNS 1 (1) 1 (2) 0 (0) .39
Aerobic GN Enterobacteriaceae 1 (1) 1 (2) 0 (0) .39
Morganella 1 (1) 0 (0) 1 (1) >.99
Hospitalization or ED visit for rUTI 51 (35) 20 (34) 31 (35) >.99
CNS, central nervous system; ED, emergency department; GN, gram-negative.
a P values were computed using Fisher's exact test.
b For UTI organisms, P values were computed for dummy variables E coli vs not E coli, Klebsiella vs not Klebsiella, and so 
forth.
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Roussey-Kesler et al5 found that the 
infecting organism was resistant 
to TMP-SMX in 73% of treatment 
group recurrences, and 49% of 
control group recurrences. Craig et 
al2 conducted a trial of prophylaxis 
among children with a history of UTI 
(but not necessarily VUR) and also 
found that resistance to TMP-SMX 
was more common in UTIs of children 
randomized to the treatment group 
(67% vs 25% in the placebo group). 
Montini et al, 6 Garin et al, 7 and Pennisi 
et al8 each reported that recurrences 
in the treatment arms were more 
likely to be caused by resistant 
pathogens, although these authors did 
not report detailed resistance data. 
In the 3-armed Swedish Reflux Study, 
Brandström et al9 observed that 
although resistant rUTIs were more 
prevalent among girls on prophylaxis 
compared with those on surveillance 
(7/8 vs 9/24 rUTIs, P = .038), there 
was no difference in resistance 
between those in the prophylaxis 
group and those in the endoscopic 
treatment group, who were not 
exposed to chronic antibiotics 
(7/8 vs 5/10 rUTIs, P = .15).
Although the RIVUR trial used 
TMP-SMX as the sole prophylaxis 
agent, resistance patterns may 
be different when other agents 
are used. Cheng et al10 found that 
among children with VUR who 
were treated with prophylaxis by 
using a variety of agents, rUTI with 
organisms producing extended-
spectrum β-lactamase was more 
common among children receiving 
cephalosporin prophylaxis compared 
with those on TMP-SMX, and that 
resistance among the TMP-SMX 
group overall increased minimally. 
Another study of breakthrough 
UTI in 56 children found resistant 
uropathogenic organisms in 78% 
of those on cefixime, 37% of those 
on cephalexin, and 37% of those on 
TMP-SMX.11
Differences in pathogen type 
between TMP-SMX–resistant 
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 FIGURE 1
Proportion of rUTI episodes resistant to TMP-SMX as a function of the timing of the episode (divided 
into 6-month blocks after enrollment), stratifi ed by TMP-SMX treatment arm versus placebo arm.
 FIGURE 2
Plot showing association of resistance to other antimicrobial agents with TMP-SMX resistance, 
among recurrent F/SUTI.
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and –susceptible infections were 
largely driven by Enterococcus, 
which, based on the metabolism of 
the organism, was not tested with 
respect to TMP-SMX resistance. 
Therefore we classified Enterococcus 
as resistant by definition. Excluding 
Enterococcus infections, proportions 
of E coli were relatively similar 
(82% E coli [42/51] among TMP-
SMX–resistant rUTI versus 89% 
E coli [79/89] among TMP-SMX–
susceptible rUTI, P = .31).
The detailed RIVUR trial data allowed 
us to perform unique analyses of 
time patterns of TMP-SMX resistance. 
We observed that the proportion of 
rUTIs that were TMP-SMX resistant 
decreased over the course of the 
study, in both the TSP treatment 
arm and the placebo arm, with 
much larger decreases in the TSP 
group. One explanation may be 
decreased medication compliance 
over time, from 90% compliance 
during the initial 2 months, to 
59% compliance during the last 2 
months (compliance was defined as 
the percentage of doses reportedly 
administered to each subject during 
the preceding 2-month time period, 
averaged over the entire group). 
We might expect the proportion 
of TMP-SMX–resistant rUTIs to 
decrease along with the decrease 
in exposure to the agent. However, 
this explanation is weakened by 
the fact that the same trend of 
decreasing TMP-SMX resistance 
was observed in the placebo group 
(albeit less dramatically than in the 
treatment group). The mechanism of 
diminishing resistance in both groups 
is uncertain, and may be different in 
each group.
Another key question addressed 
by this analysis is whether rUTIs 
are more common if the index UTI 
was resistant to the agent used for 
prophylaxis. Craig et al2 reported 
that if the index UTI was TMP-SMX 
sensitive, TSP was associated with 
decreased rUTI; but, if the index 
UTI was TMP-SMX resistant, then 
TSP was not effective. However, 
these authors did not report the 
impact of index UTI resistance on 
recurrence for the treatment group 
specifically. The Campbell-Walsh 
Urology textbook12 states (without 
citing any published data) that the 
agent chosen for prophylaxis should 
be different from the one used to 
treat the index UTI, because the fecal 
flora are likely to be resistant to the 
therapeutic agent and thus the risk of 
rUTI is high if the same agent is used 
for prophylaxis. Clinicians routinely 
must decide whether to use the index 
UTI antibiogram to guide their choice 
of prophylaxis agent. Our results 
failed to demonstrate any difference 
in overall incidence of rUTI among 
the TSP arm based on index UTI 
resistance to TMP-SMX; although 
7
TABLE 3  Incidence of rUTI, Stratifi ed by Resistant Versus Susceptible Index UTI, Among RIVUR Subjects Randomized to TMP-SMX Treatment, With Cox 
Proportional Hazards Survival Analysis
Outcome/Exposure Unadjusted Adjusteda
No. With rUTI/No. at Risk (%) Time to 10% incidence daysb HR (95% CI) HR (95% CI) Pc
Recurrent UTI
All treatment arm subjects 34/278 (12) 428 N/A N/A N/A
Index UTI TMP-SMX resistant 7/ 55 (13) 123 1.13 (0.49–2.60) 1.38 (0.54–3.56) .50
Index UTI TMP-SMX susceptible 27/223 (12) 541 Reference Reference N/A
a Adjusted for febrile index UTI, age, race, ethnicity, VUR, BBD, and site.
b The time interval (days) between enrollment and a 10% incidence of events.
c Calculated using the Wald χ2 test statistic.
 FIGURE 3
Survival plot showing proportion of children experiencing rUTI during follow-up period, comparing 
those with susceptible versus resistant index UTI, among children in the TSP treatment arm of the 
RIVUR study.
 NELSON et al 
the timing pattern of rUTI differed 
somewhat between the groups, the 
overall incidence of UTI was similar, 
suggesting that TSP is a reasonable 
option for prophylaxis in children 
with TMP-SMX–resistant index UTI. 
In practice, the choice of prophylaxis 
agent is based on a number of factors, 
including the patient’s age, allergies, 
the prescriber’s experience and 
comfort with certain agents over 
others, and the history of previous 
treatment with antibiotics.
CONCLUSIONS
Although rUTIs that occurred among 
children with VUR receiving TSP 
were more likely to be caused by 
TMP-SMX–resistant organisms 
than rUTIs among children in the 
placebo group, there was no clinically 
significant difference between groups 
in the proportion of children who 
experienced TMP-SMX–resistant 
rUTI. The frequency of TMP-SMX–
resistant infections decreased 
substantially as duration of therapy 
increased, in both the treatment and 
placebo arms. Resistance of the index 
UTI to TMP-SMX does not reduce 
the efficacy of prophylaxis with this 
agent to prevent rUTI among children 
with VUR.
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